THE linking together of experimental medicine with therapeutics as the special concern of our Section presupposes some connexion between the two. Nevertheless there is a point of view that this relationship is casual rather than functional and that the main advances in therapeutics have been based on empiricism rather than on the experimental study of the phenomena of disease. This is certainly true of the treatment of hypertension. Nothing could be more empirical than the devices which first the surgeons, and then the manufacturing chemists, have, in turn, provided for the relief of high blood pressure. It is, however, an axiom in therapeutics that the primary concern of the physician is not with the mode of action of a drug but with its effect on the natural history of the disease in the individual patient.
Yet I believe that in the search for further advances in treatment new problems have arisen which have brought therapeutics into closer relation with experimental medicine. This new alliance has been most productive in the treatment of metabolic disorders and of chronic diseases. The treatment of dehydration, the correction of electrolyte deficiencies, and the selective effects of radioactive isotopes are examples. In chronic disease the main problem has been the assessment of new forms of therapy. Here again the experimental method has been applied with great success in the planning of controlled therapeutic trials. This new form of investigation has made a valuable contribution to our knowledge of the natural history of disease; firstly by evolving methods for the quantitative analyses and assessment of prognosis, and secondly by applying these, not only in the treated but also in the untreated patient. Finally there are some diseases, such as hypertension, in which the experimental method has uncovered some of the specific mechanisms of the pathological process, thereby leading to a closer understanding of its natural history and to greater accuracy in diagnosis.
In selecting for my Address the subject Experiment and Therapy in Hypertension I had in mind some of these relationships between the experimental method and therapeutics. I do not intend to present any detailed results either of experimental investigations in hypertension or of the various forms of treatment now in vogue. At the present time, I think it is more appropriate to offer you some reflections on present-day therapy of hypertension from the points of view of its rationale, the basis of selection and assessment of cases, its effectiveness or otherwise, and the contribution which it may have made to our further understanding of the patients we are trying to treat. DIAGNOSIS One of the conditions which must be fulfilled before the results of treatment can be more satisfactorily assessed is greater accuracy in diagnosis. In the very numerous published reports, particularly on the surgical treatment of hypertension, most authors pay scant attention to diagnosis. Admittedly it can be a difficult problem, especially in patients with 280 Proceedings of the Royal Society of Medicine 10 early renal involvement, to decide between essential and renal hypertension and between the various causes of the latter. Unfortunately this is the group of patients in whom lowering of the blood pressure may be most urgently indicated. In carrying out sympathectomy the surgeon has a unique opportunity to make an accurate diagnosis of the pathological lesion, since renal biopsy can be easily and safely performed during the operation. I shall present a few observations we have made from examination of biopsy specimens in some 50 patients who have been treated by this operation. The rationale for treatment of high blood pressure can never be determined in the individual patient unless the primary diagnosis is fully understood. By this I mean not merely the placing of a label on a particular case, but, what is more important, taking into account the stage of the natural history at which treatment is commenced and recognizing the particular aspects of the pathological lesion which materially affect prognosis. I shall refer to those in detail when discussing assessment, but two examples will illustrate the argument. During the pre-war years an examination at the London Hospital of 56 cases of malignant essential hypertension, verified histologically, gave an average expectation of life of one year. At the present time, owing to the common practice of routine blood-pressure examinations for national service, life insurance and public employment, severe hypertension is being discovered with increasing frequency in young subjects and the development of features suggesting a transition to the malignant phase is being detected very early in the disorder. Our concept of the natural history of malignant essential hypertension therefore differs significantly from the one which was derived from pre-war studies. It follows that a comparison between a series of cases treated now, with untreated or differently treated cases described by other writers in previous years, may well be invalid. A second source of fallacy in therapeutic assessment is the grouping together of cases with the malignant type of hypertension, without clear evidence of the primary disorder. Now the natural prognosis is bad in malignant hypertension whatever the primary cause; but it is of first importance when selecting patients for treatment, no less than when assessing results, to know whether the kidney is relatively normal in structure as in the early cases of malignant essential hypertension, or whether it is grossly disorganized as in most cases of chronic nephritis.
In view of these considerations, I shall now discuss separately the different wetiological varieties of hypertension.
ESSENTIAL HYPERTENSION
Several operative procedures for the relief of essential hypertension have been employed in the last thirty years. Anterior rhizotomy was first used by Adson and the patients selected were said to be suffering from malignant hypertension. Since then various types of sympathetic resection have been carried out. It is very rare in the published reports to find any discussion of the specific reasons for operation. In general, the objective appears to have been lowering of the blood pressure, if possible to normal, in order to avoid complications in the heart, brain, retina or kidneys. Smithwick recently stated, however, that he. no longer assesses his results on the fall in blood pressure produced but on statistical analysis of the survival period compared with patients treated medically. Such a criterion is of practical importance in a comparison of techniques, but it is of little value to the individual patient. There are I believe two principal reasons why active treatment may be considered necessary in essential hypertension, (1) the risk of chronic arterial degeneration (i.e. atheroma) leading to ischemic heart disease, retinal lesions or cerebral vascular catastrophes, (2) the danger of malignant hypertension with its grave prognosis due to renal, cerebral, retinal and cardiac damage. There is a smaller group of patients who show no evidence of either of these distinct types of vascular complication, but who suffer from disabling symptoms, especially early morning or migrainous hleadaches, which appear to be a direct consequence of severe hypertension. Relief of these symptoms may be a proper aim of therapy.
Taking first the risk of chronic arterial degeneration and its sequelk, hypertension is only one predisposing factor in the production of atheroma; there are several others-mechanical stress at focal points in the arterial system, the particulate state of circulating lipoids, obscure metabolic factors such as operate in diabetes, and probably hereditary predisposition. Yet in essential hypertension chronic arterial degeneration may not develop for ten, twenty or thirty years, during which period the patient may be free from symptoms. At what point in this long course should hypotensive therapy be applied and is it necessary for the blood pressure to be restored to normal? Since hypertension often returns to pre-operative levels after sympathectomy, is this form of treatment of any avail in preventing or reducing the development of severe atheroma? Should operation or drug therapy be withheld until signs of arterial disease appear? Atheroma may be focal in its incidence and irregular in distribution so that severe involvement of coronary or cerebral arteries may be present although all available investigations for arterial degeneration fail to reveal its presence.
Moreover, once organic vascular damage has occurred in the heart or brain, sudden reduction Section of Experimental Medicine and Therapeuttes 281 of the blood pressure level may do more harm than good. In the individual patient we have no method by which we can even approximately foreshadow the development or results of atheroma. In benign essential hypertension therefore the prevention of chronic arterial degeneration seems to be an inadequate reason for employing such a drastic and uncertain form of treatment as sympathectomy. Nevertheless I think the questions I have asked need to be studied. There is no doubt that high blood pressure predisposes to obliterative arterial disease and its consequences, and the expectation of life is thereby shortened. It is possible that a large-scale investigation in which clinicians, morbid anatomists and biochemists took part, might demonstrate that modification of hypertension by drug treatment reduces the hazards of atheroma. Such an investigation would have to be planned and controlled on the same lines as therapeutic trials of antibiotics in chronic infectious disease.
Here is a field in which the experimental method might be appropriately applied to a therapeutic problem which is rapidly increasing in size and in urgency.
The other indication-the risk of malignant hypertension-is in a different category and it is at this point that the study of experimental hypertension may help us to understand the nature of the problem more clearly. In the first place we have convincing evidence that hypertension-independent of any metabolic abnormality-is the prime factor in producing the acute arteriolar necroses which are the most serious consequence of malignant hypertension. Secondly there is strong presumptive evidence from the recent work of Byrom that in malignant hypertension the arterioles of the brain, and probably of the splanchnic area, may pass into a state of excessive focal vasoconstriction. Such focal vasoconstriction or its consequences may well be the basic disturbance which is responsible for acute hypertensive retinopathy, encephalopathy, pulmonary cedema and renal arteriolar necrosis. Thirdly, in animal experiments, both arteriolar necrosis and focal spasm can be halted or prevented by lowering the blood pressure. Fourthly, if malignant hypertension persists, extensive renal vascular damage may set in motion a vicious circle which maintains the hypertension and renders the process irreversible. These considerations provide clear indications for the prompt relief of hypertension. The essential requirement is to produce an effective lowering of blood pressure before irreversible changes are produced in the kidneys. This objective poses two further questions: first, what is an effective lowering of the blood pressure? I think the answer is as close an approximation to normal as possible, for restoration to normal is rarely practicable and perhaps unnecessary. If papillcedema regresses and further renal damage is prevented treatment is well justified, but unless an appreciable fall in blood pressure is maintained, the ultimate prognosis remains poor, for the reversibility of malignant essential hypertension is far more difficult and uncertain than the reversal of the malignant renal hypertension which may follow removal of a single diseased kidney.
The second question is, can the development of the malignant phase be anticipated? The diagnostic sign of malignant hypertension is papilloedema, and it is not possible in the absence of this sign to forecast with certainty the transition to the malignant phase. In certain cases of severe benign hypertension the imminence of this transition is sometimes suspected. For example, the development of severe headache associated with a fixed diastolic pressure, over 130 mm., in a young male subject is an ominous sign, and if the diastolic pressure is rising it is even more so. The appearance of retinal hTmorrhages with or without exudates, or the occurrence of an isolated attack of encephalopathy, characterized for example by severe frontal headache, a convulsion, loss of consciousness or transient paresis-all these suggest a qualitative change in the character of the peripheral vascular disorder from the benign to the malignant type.
It is in this group that sympathectomy and hypotensive drug therapy are often most effective in lowering the blood pressure and relieving symptoms. Far more attention should be paid to the natural prognosis and the renal histological changes in these patients. Most of them show retinopathy in the form of retinal haemorrhages which may be associated with exudates but without papillcedema. I should like to refer here to a common practice, especially in the United States, of grading hypertension according to the severity of lesions in the retina. The patients I have just described are graded as Group III. If retinal haemorrhages are close to the disc there is often some degree of papilleedema and presumably the hypertension is then graded as Group IV. However, such papilloedema does not necessarily indicate malignant hypertension. It is almost invariably unilateral and subsides as the retinal lesions regress. This grading of high blood pressure is useful in emphasizing the importance of retinal lesions, but it neglects, and I think this is most serious, the variations in course and prognosis which the patients in this transitional group exhibit. The hallmark of a good classification is that its subgroups are homogeneous. There is evidence that a proportion of patients with so-called Grade III hypertension develop the malignant change but we have insufficient information to say what proportion; there are others, however, (particularly women) who continue for many years, with or without recurrence of the above 282 Proceedings of the Royal Society of Medicine 12 symptoms, and we cannot be certain that papilleedema or renal involvement will ultimately appear. It is probably justifiable to attempt to lower the blood pressure in these patients by surgical or medical means; what is unjustifiable is to regard them as examples of malignant hypertension or even as a homogeneous group in assessing the value of a particular form of therapy. Fig. 1 Bilateral lumbo-dorsal sympathectomy produced a temporary fall in blood pressure with relief of symptoms but two years later the blood pressure had returned to pre-operative levels and has continued there for three years without any evidence of transition to the malignant phase. No papilleedema or clinical evidence of renal involvement has been observed at any stage yet histological examination of renal biopsy material taken at the time of operation shows the characteristic glomerular and arteriolar necroses of malignant hypertension (Fig. 2 ). Whilst it could be argued that in this patient sympathectomy and later the administration of hypotensive drugs had prevented the transition from the benign to the malignant phase, a similar protracted course is not infrequently observed in other patients of this type who have had no hypotensive therapy. I come now to those patients in whom the diagnosis of malignant essential hypertension is unequivocally established by the finding of bilateral papillcedema. In assessing the results of treatment, attention is naturally focused on the reversal of papilluedema and the absence of progressive vascular damage as evidenced by improvement in albuminuria and renal function, or at any rate no further deterioration. It is important to realize that activity, in the sense of production of arteriolar necrosis, is not continuous in malignant hypertension. It is more often phasic and may possibly in some cases be confined to a single episode. Histological examination of the kidney quite commonly reveals only organized lesions of the renal arterioles and glomeruli, without evidence of recent acute arteriolar necrosis. It was this observation which led Fahr to describe endarteritis rather than necrotizing arteriolitis as the diagnostic lesion of malignant nephrosclerosis. Examination of renal biopsy sections from early cases of malignant hypertension more often shows healed than acute vascular changes, i.e. in these patients operation has been performed during a quiescent period after an acute hypertensive episode.
The clinical findings in this inactive stage show the same freedom from acute disturbances. Most characteristic are the optic fundi. The discs, though indistinct at the margins and still showing lack of definition of the optic cups, reveal no measurable papilleedema and new hlmorrhages and exudates are not observed. This appearance is sometimes called chronic papilloedema or secondary optic atrophy. It is better regarded as a sign of quiescence of the specific focal vasoconstriction which characterises malignant hypertension. In selecting patients for operation, or in assessing prognosis and response to treatment, awareness of this phasic character of the disease and recognition of the active and quiescent states appear to be of considerable importance.
As a result of combined clinical, histological and experimental observations we have reached a much clearer understanding of the condition which Allbutt sixty years ago called hyperpiesia. Allbutt separated this condition from renal hypertension, because clinical evidence of renal involvement was not observed during the whole course of the disease. We now have convincing evidence that severe "hyperpiesia" may lead to involvement of the kidneys-and other organs-by the production of necrotizing vascular lesions, and clinically we recognize this malignant phase of the disease by the appearance of papilleedema. Just as nephrosclerosis is now accepted as the late irreversible stage of renal damage in this malignant phase I would suggest that papilleedema is a sign, in the great majority of untreated cases, of an irreversible functional stage. Both these late manifestations may be preceded by hypertensive crises in which transient symptoms of malignant hypertension may occur and focal vascular necrosis may be produced. Whether or not this phasic disorder passes into the irreversible stage of malignant nephrosclerosis depends on factors we do not fully understand, but this sequence is by no means inevitable; in support of this is the occasional finding of healed acute hypertensive lesions in the glomeruli and renal arterioles in patients who have followed a typical clinical course of benign hypertension.
There is still a place for sympathectomy in early malignant hypertension. The response to hypotensive drugs may be poor, side-effects may be incapacitating, the patient may not co-operate sufficiently to persevere with drug treatment or the necessary supervision may not be available. When, however, more than a slight degree of nitrogen retention is present and concentration tests are impaired, or when a previous cardiac infarction or cerebral hiemorrhage makes the surgical risk unjustifiable, treatment with drugs of the hexamethonium group is of undoubted value. Severe headaches may be relieved and vision improved; attacks of encephalopathy often respond dramatically within a few hours and cardiac asthma may subside. Our observations on renal function during the course of drug treatment are still rather scanty but so far we have obtained no evidence either of improvement or of sudden deterioration that could be attributed to the treatment. The same conclusions were reached about the influence of sympathectomy on renal function in the early days of treatment. Patients with malignant hypertension subjected to bilateral sympathectomy showed no significant improvement in renal function apart from possible reversal of extrarenal nitrogen retention. It appears then that impairment of renal function in malignant hypertension is in the main due to irreversible organic changes; and furthermore if the blood pressure level is subsequently lowered, internal regulating mechanisms in the surviving renal tissue are capable of maintaining function relatively unchanged.
CHRONIC NEPHRMTIS
The indications for treatment and the form of therapy to be employed in chronic nephritis are in my view rather different from the foregoing. This conclusion is based on two considerations; first, that structural renal damage is always severe in chronic nephritis, and second that once the blood pressure has reached a high level, e.g. 200 mm. systolic, the malignant change develops much more frequently than in essential hypertension. Many years ago, Dr. Kimmelstiel and I found that in a post-mortem series of 250 consecutive cases of essential hypertension less than 5 % presented the histological features of malignant hypertension.. If the estimate were confined to the younger age groups covering the main incidence of chronic nephritis it is possible that this figure might be somewhat higher, possibly double; but it would not approach the incidence of terminal malignant hypertension in chronic nephritis, which is over 50%. The figure is approximately the same for both Type I and Type II nephritis. It is interesting also that this is roughly the incidence of malignant hypertensive lesions in rats with experimental renal hypertension. I feel therefore that when the blood pressure rises towards the 200 mark in chronic nephritis, whether retinopathy is present or not, an attempt should be made to reduce the level. It might be questioned whether reduction of blood pressure is justified in chronic nephritis to the same extent as in essential hypertension. One can only say there is no evidence either that a high blood pressure is beneficial in chronic nephritis or that lowering the pressure to a more moderate figure causes further impairment of renal function. There is, on the other hand, both clinical and histological evidence, especially in chronic Type I nephritis, that progressive renal damage follows the development of a high blood pressure. This "hypertensive transformation" is a very characteristic feature of chronic nephritis. It may occur over a relatively short period of six months or so following many years of fairly stable, slight to moderate, hypertension. Why this phenomenon should occur is not clear. There is no evidence at this stage of exacerbation of the nephritis such as may occasionally be accountable for hypertensive crises early in the disease. This is confirmed by the failure to find fresh lesions of glomerulo-nephritis on histological examination. It seems more probable that gradually increasing ischemic damage in glomeruli and arterioles, possibly hastened by advancing age, eventually oversteps the threshold at which progressive hypertension develops. Whatever the explanation, this phenomenon is usually associated with rapid deterioration in renal function. Following this, there is then a considerable likelihood that, usually within a year in men and rather longer in women, the hypertension will enter its malignant phase, with clinical features differing from malignant essential hypertension only in the greater prominence of uremic symptoms. aches, myocardial failure, hypertensive encephalopathy and retinopathy. I feel less sanguine about the value of hypotensive treatment in chronic Type II nephritis. The malignant termination is if anything more common in this condition than in Type I. Whilst symptomatic improvement at this stage may be expected from hypotensive drugs I doubt whether their use at an earlier stage has in any of our patients increased the expectation of life. This is what might be anticipated from a study of the renal lesion, which is invariably a diffuse progressive glomerulo-nephritis. Even after a malignant termination it is unusual to find on microscopic examination secondary hypertensive changes in the kidneys, i.e. in this form of nephritis it seems unlikely that hypertension, even of the malignant type, is responsible for any appreciable degreo of structural renal damage. It may, of course, produce fatal vascular lesions in other organs but this is not common.
It is necessary to mention at this point that malignant episodes of hypertension occasionally undergo spontaneous reversal in chronic nephritis. Such episodes have been observed in two circumstances. Firstly in chronic nephritis complicated by pregnancy. These patients may develop papilloedema and eclamptic fits towards the end of pregnancy or more rarely in the puerperium. The condition is often wrongly diagnosed as pregnancy toxaemia, the pre-existing renal lesion being unrecognized. Spontaneous resolution of papilloedema and improvement in renal function is not infrequent after delivery but the blood pressure may continue at a high level. A similar sequence of events is occasionally seen in the early stages of chronic Type II nephritis. In these patients there is usually clear-cut evidence of an exacerbation of the nephritis with increase in cedema, some degree of hxematuria and deterioration in renal function. As the exacerbation subsides a coincident reversion from the malignant to the benign type of hypertension may occur. These features in the natural history of nephritis must obviously be taken into account when hypotensive treatment is contemplated or the results are being assessed. BILATERAL PYELONEPHRITIS AND HYDRONEPHROSIS These conditions are not usually accompanied by a degree of hypertension which requires specific treatment. Nevertheless we have in our records a number of patients in whom severe hypertension, occasionally progressing to the malignant stage, has been apparently caused by one or other or a combination of both these processes. In 3 cases, all children, the advanced degree of hydronephrosis seemed to indicate a congenital maldevelopment. A period of improvement, with reversal of the malignant hypertension, has followed sympathectomy. It is essential in such cases that the possibility of a local obstructive cause should be looked for and if found, corrected. In view of the considerable reduction in renal tissue and associated infection in hydronephrosis, drug treatment rather than sympathectomy is at present to be preferred.
One point which has emerged from our study of renal biopsy sections after sympathectomy is the occasional impossibility in detecting chronic pyelonephritis without histological examination. In one case renal biopsy showed bilateral pyelonephritis without contraction, although full investigation had revealed no abnormality in the urine, renal function or intravenous pyelogram. It seems inevitable therefore that in the selection of patients with essential hypertension or chronic nephritis for hypotensive drug treatment there is a definite risk that a few cases of chronic pyelonephritis will be included in error.
UNILATERAL RENAL DISEASE
The occurrence and natural history of hypertension in unilateral renal disease is particularly relevant since it presents a striking parallel with experimental hypertension in animalsespecially in the rat. This parallel can be extended even more remarkably to the therapeutic response, since removal of the abnormal kidney abolishes hypertension in only about 50% of cases-a similar proportion to that which obtains after unilateral nephrectomy in hypertensive rats. There is now convincing proof from our original and from more recent experiments that persistent hypertension in the rat after removal of the clamped kidney is attributable to secondary hypertensive damage in the opposite kidney. Similar hypertensive changes are commonly observed in the contralateral kidney in man, and it seems a fair presumption that they account for the fact that in some cases the hypertension is not abolished after nephrectomy, and in others may even rise to a higher level than before operation. It is therefore a wise precaution before nephrectomy to make certain by ureteric catheterization that urine from the contralateral kidney shows no evidence of active renal damage.
The reversal by nephrectomy of malignant hypertension in unilateral renal disease is one of the most satisfying and dramatic results of treatment. Nevertheless it should not be assumed that other forms of malignant hypertension are similarly reversible. Two conditions are necessary to abolish malignant hypertension: (1) the primary cause of the hypertension must be removed, and (2) secondary hypertensive renal damage must not have passed a certain critical stage. In the common forms of malignant hypertension, i.e. complicating essential hypertension or chronic nephritis, the cause of the hypertension cannot be removed and, except in the very early stages, secondary hypertensive renal damage is always severe. All one can expect in treating these conditions is to neutralize in part the intense vasoconstriction of malignant hypertension by superimposing a physiologicatly different vasodilator effect. But the cause of the malignant hypertension remains; I have seen a patient with essential hypertension develop papillcedema on three occasions, the first time before operation and the second and third times during relapse after successive sympathectomies of increasing extent. This thesis is aptly illustrated in the rare type of hypertension due to phwochromocytoma of the adrenal. Paroxysmal hypertension due to this tumour, after a variable interval, tends to become permanent and may pass into the malignant stage. The early paroxysmal hypertension is relieved by removal of the tumour but the later fixed hypertension usually persists after operation. In these patients, even though the primary cause of the hypertension is removed, the condition may be rendered irreversible by the development of secondary hypertensive lesions in the kidneys.
THE ADRENAL CORTEX AND HYPERTENSION In conclusion, it is difficult to avoid some comment on the relationship between the adrenal cortex and hypertension. I am aware that there are many causes of high blood pressure and that the body has a limited choice of functional and structural responses to a wide variety of environmental hazards. Nevertheless, ever since I observed, some twenty years ago, the features of benign and malignant essential hypertension reproduced in patients with Cushing's syndrome I have wondered whether the common forms of high blood pressure might not have some endocrine basis; this impression was strengthened when it became apparent that Cushing's syndrome could arise in the absence of any apparent structural abnormality in the adrenal cortex. Before entering this speculative field I must emphasize that at present there is no evidence that in man the adrenal cortex secretes a hormone which causes either essential or renal hypertension. In the rat, the hypertension which follows either renal artery constriction or total nephrectomy is abolished if the adrenals are removed. Whether this adrenal factor independently maintains a background of arteriolar tone on which other forms of vasoconstriction are superimposed, or alternatively whether the kidney directly influences this adrenal mechanism is a vital but as yet an undecided problem. Such evidence as we have points to the latter, i.e. that the normal kidney in some way inactivates a pressor factor derived from the adrenal cortex. Moreover the evidence suggests that the excess of this pressor factor in experimental renal hypertension is not due to its over-production by the adrenal cortex but to failure of the kidney to deal with the normal cortical output. Since deoxycortone acetate or even increased salt intake can act as effective substitutes for the adrenal cortex in these experiments it seems likely that the adrenal pressor factor acts through some influence on tissue electrolyte distribution. There is a possible relevance here to the effect of sodium restriction on hypertension in man, and the variable reponse to this form of therapy may be attributable to the influence of the intact adrenal glands. Thus in rats variations in salt intake have little effect on renal hypertension when the adrenals remain intact.
These experimental findings obviously provide no rational basis for adrenalectomy in the treatment of human hypertension. If indeed renal or essential hypertension in man were due to the same mechanism as experimental hypertension in the rat, removal of the adrenals would not improve the situation, since, in order to keep the patient alive, substitution therapy would, of necessity, restore the normal supply of adrenal pressor factor without correcting the abnormality of its regulation. This is indeed what appears to happen for, from reports in the literature, it seems that when patients with essential or renal hypertension are submitted to total adrenalectomy it is subsequently very difficult to prevent cortical insufficiency without elevating the blood pressure. Moreover in these adrenalectomized subjects physiological doses of cortisone are sufficient to restore hypertension, which supports the view that overaction of the adrenal pressor mechanism is not involved (Fig. 4) different in those patients whose hypertension is associated withCushing's syndrome. Here, removal of an adrenal tumour or subtotal adrenalectomy will cause prompt reversal of Cushing's syndrome and a return to the eucortical state without recurrence of the hypertension (Fig. 5 ).
I think it is along these lines that future developments may take place. Here and there surgeons are performing the operation of total adrenalectomy for various reasons. Whilst this practice may not commend itself entirely to us in the realm of therapeutics it does offer a remarkable opportunity for our more rational activities in the sphere of experimental medicine.
